MetaCap

BioMarin Pharmaceutical (BMRN) vs Spyre Therapeutics (SYRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Spyre Therapeutics (SYRE) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 285.3% versus a gain of 10.5%. Over five years, BMRN leads with a -31.0% price change compared with -42.0% for SYRE. BioMarin Pharmaceutical is the larger company by market cap ($11.70 billion vs $8.88 billion), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BMRN+10.46%SYRE+285.28%
+367%+170%-27%
Nov 21, 20251 yearNov 20, 2026
BMRN-33.96%SYRE-44.03%
+35%-35%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BMRN versus SYRE key metrics
MetricBMRNSYRE
Share price$60.41$93.47
Market cap$11.70B$8.88B
1-day change-1.64%-4.26%
YTD return+1.65%+185.32%
1-year return+10.46%+285.28%
5-year return-31.02%-42.03%
Forward P/E9.60—
EPS (TTM)$-0.10$-2.49
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.22B$0
Revenue growth (YoY)+12.87%—
Net income (latest FY)$348.90M$-155.20M
Gross margin77.73%—
Operating margin12.71%—
Net margin10.83%—
52-week high$70.98$110.64
52-week low$49.26$24.58
Distance from 52-week high-14.89%-15.52%
Analyst consensusbuystrong_buy
Avg. price target upside+49.48%+32.52%
Average volume2.35M1.26M
Shares outstanding193.69M94.97M
Employees3,221130
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SYRE has outperformed BMRN by 274.8 percentage points over the past year.

About BioMarin Pharmaceutical

BMRN stock →

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.

Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees

About Spyre Therapeutics

SYRE stock →

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).

Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees

BMRN vs SYRE FAQ

Which is bigger, BioMarin Pharmaceutical or Spyre Therapeutics?

BioMarin Pharmaceutical (BMRN) is larger, with a market capitalization of $11.70B compared with $8.88B for Spyre Therapeutics (SYRE).

Which stock has performed better over the past year, BMRN or SYRE?

SYRE returned +285.28% over the past 12 months, compared with +10.46% for BMRN (price return, excluding dividends). Past performance does not predict future results.

Are BioMarin Pharmaceutical and Spyre Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons